Skip to content

Co-packaged AZT/3TC/efavirenz regimen approved for use in PEPFAR programmes

Ethiopia to provide ARVs to 50,000 by July

Treatment started early in HIV infection effective and well tolerated for up to five years

Genotypic resistance testing on a failing regimen is possible below 1000 copies/ml

Five cancers seen in vicriviroc study `not causally related`, study continues

New directions in HIV prevention: serosorting and universal testing

New directions in HIV prevention: circumcision and PREP

Best results in HIV-positive children if treatment started before five months of age

Merck announces 20% cut in efavirenz price for low and middle-income countries